Roles of microRNA‑186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus

Yuan,Weidong; Li,Fuguang

doi:10.3892/etm.2020.9092

Roles of microRNA‑186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus

Authors:
- Weidong Yuan
- Fuguang Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China, The Second Ward of General Surgery Department, Ankang City Central Hospital, Ankang, Shaanxi 725000, P.R. China
Published online on: August 3, 2020 https://doi.org/10.3892/etm.2020.9092
Pages: 3860-3867

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aims to investigate the role and underlying mechanism of microRNA (miR)‑186 in patients with hepatocellular carcinoma (HCC) complicated with portal vein tumor thrombus. Blood samples from 29 HCC patients with portal vein tumor thrombus were collected between January 2014 and September 2015 in Huai'an First People's Hospital, while blood from 36 HCC patients without vein tumor thrombus was also collected in the same period. In addition, tumor thrombus specimens were collected from the HCC patients with portal vein tumor thrombus, and peritumoral tissues of the tumor thrombus were used as the control. Reverse transcription‑quantitative polymerase chain reaction, ELISA and western blot analyses were applied to detect vascular endothelial growth factor (VEGF) expression at the mRNA and protein levels. Bioinformatics prediction was used to predict the target of miR‑186, and then miR‑186 expression was detected. Furthermore, dual‑luciferase reporter assay was used to validate whether miR‑186 directly targeted VEGF. Following transfection with agomiR‑186, the expression levels of miR‑186 and VEGF were detected, while MTT assay was used to detect EA.hy926 cell proliferation subsequent to small interfering RNA (siRNA) silencing. The results identified that VEGF was significantly increased in the tumor thrombus and blood samples of HCC patients with vein tumor thrombus at the mRNA and protein levels, while miR‑186 expression was significantly decreased (P<0.05). Following silencing VEGF by siRNA transfection, the proliferation of EA.hy926 cells was inhibited. In addition, VEGF expression was significantly decreased and cell proliferation was reduced when upregulating miR‑186. Dual‑luciferase reporter assay demonstrated that miR‑186 regulated VEGF expression through complementary binding to 3'‑untranslated region. In conclusion, VEGF was significantly increased in tumor thrombus and blood samples from HCC patients with vein tumor thrombus, which may be associated with the downregulation of miR‑186. Thus, miR‑186 may promote the development and progression of vein tumor thrombus in HCC.

View Figures

View References

1	Kanda M, Sugimoto H and Kodera Y: Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 21:10584–10597. 2015.PubMed/NCBI View Article : Google Scholar
2	Kuszyk BS, Beauchamp NJ Jr and Fishman EK: Neurovascular applications of CT angiography. Semin Ultrasound CT MR. 19:394–404. 1998.PubMed/NCBI View Article : Google Scholar
3	Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W and Biggins SW: Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 21:1543–1552. 2015.PubMed/NCBI View Article : Google Scholar
4	Yang BH, Xia JL, Huang LW, Tang ZY, Chen MS, Li JQ, Liang AM, Mo QG, Lu HS, Dai CL, et al: Changes of clinical aspect of primary liver cancer in China during the past 30 years-control study for 3,250 cases with primary liver cancer. Zhonghua Yi Xue Za Zhi. 83:1053–1057. 2003.(In Chinese). PubMed/NCBI
5	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011.PubMed/NCBI View Article : Google Scholar
6	Trousseau A: Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris: Translated and edited with notes and appendices, by P. Victor Bazire. Lindsay and Blakiston, 1869.
7	Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ and Rosendaal FR: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J Thromb Haemost. 4:529–535. 2006.PubMed/NCBI View Article : Google Scholar
8	Meyer G: Venous thromboembolism and cancer. Rev Prat. 65:216–219. 2015.(In French).
9	Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer W, Zielinski CC, Pabinger I, et al: Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Thromb Res. 136:865–869. 2015.PubMed/NCBI View Article : Google Scholar
10	Malaponte G, Signorelli SS, Bevelacqua V, Polesel J, Taborelli M, Guarneri C, Fenga C, Umezawa K and Libra M: Increased levels of NF-kB-dependent markers in cancer-associated deep venous thrombosis. PLoS one. 10(e0132496)2015.PubMed/NCBI View Article : Google Scholar
11	Connolly GC, Phipps RP and Francis CW: Platelets and cancer-associated thrombosis. Semin Oncol. 41:302–310. 2014.PubMed/NCBI View Article : Google Scholar
12	Chang LH, Pan SL, Lai CY, Tsai AC and Teng CM: Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-mediated angiogenesis. Am J Pathol. 183:566–575. 2013.PubMed/NCBI View Article : Google Scholar
13	Lee S and Goldfinger LE: RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells. FASEB J. 28:4158–4168. 2014.PubMed/NCBI View Article : Google Scholar
14	Posch F, Thaler J, Zlabinger GJ, Königsbrügge O, Koder S, Zielinski C, Pabinger I and Ay C: Soluble Vascular Endothelial Growth Factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). Clin Cancer Res. 22:200–206. 2016.PubMed/NCBI View Article : Google Scholar
15	Arutyunyan I, Fatkhudinov T, Kananykhina E, Usman N, Elchaninov A, Makarov A, Bolshakova G, Goldshtein D and Sukhikh G: Role of VEGF-A in angiogenesis promoted by umbilical cord-derived mesenchymal stromal/stem cells: In vitro study. Stem Cell Res Ther. 7(46)2016.PubMed/NCBI View Article : Google Scholar
16	Gapizov SS, Petrovskaya LE, Shingarova LN, Svirschevskaya EV, Dolgikh DA and Kirpichnikov MP: The effect of TNF and VEGF on the properties of Ea.hy926 endothelial cells in a model of multi-cellular spheroids. Acta Naturae. 10:34–42. 2018.PubMed/NCBI
17	Wei Y, Yang Q, Zhang Y, Zhao T, Liu X, Zhong J, Ma J, Chen Y, Zhao C and Li J: Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells. Oncotarget. 8:15230–15241. 2017.PubMed/NCBI View Article : Google Scholar
18	Ladizinski B and Federman DG: Trousseau syndrome. CMAJ. 185(1063)2013.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Rehmsmeier M, Steffen P, Hochsmann M and Giegerich R: Fast and effective prediction of microRNA/target duplexes. RNA. 10:1507–1517. 2004.PubMed/NCBI View Article : Google Scholar
21	Witkos TM, Koscianska E and Krzyzosiak WJ: Practical aspects of microRNA target prediction. Curr Mol Med. 11:93–109. 2011.PubMed/NCBI View Article : Google Scholar
22	Peterson SM, Thompson JA, Ufkin ML, Sathyanarayana P, Liaw L and Congdon CB: Common features of microRNA target prediction tools. Front Genet. 5(23)2014.PubMed/NCBI View Article : Google Scholar
23	Li J, Xia L, Zhou Z, Zuo Z, Xu C, Song H and Cai J: MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cell by targeting ZEB1. Arch Biochem Biophys. 640:53–60. 2018.PubMed/NCBI View Article : Google Scholar
24	Su BB, Zhou SW, Gan CB and Zhang XN: MiR-186 inhibits cell proliferation and invasion in human cutaneous malignant melanoma. J Cancer Res Ther. 14 (Suppl):S60–S64. 2018.PubMed/NCBI View Article : Google Scholar
25	Thodiyil PA and Kakkar AK: Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 87:1076–1077. 2002.PubMed/NCBI
26	Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC and McKiernan JM: Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology. 69:1054–1058. 2007.PubMed/NCBI View Article : Google Scholar
27	Karnes RJ and Blute ML: Surgery insight: Management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 5:329–339. 2008.PubMed/NCBI View Article : Google Scholar
28	Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ and Figlin RA: Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 65:235–262. 2008.PubMed/NCBI View Article : Google Scholar
29	Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E and Haanen JB: Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 49:520–523. 2010.PubMed/NCBI View Article : Google Scholar
30	Harshman LC, Srinivas S, Kamaya A and Chung BI: Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol. 6:338–343. 2009.PubMed/NCBI View Article : Google Scholar
31	Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ and Perrotte P: Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 53:845–848. 2008.PubMed/NCBI View Article : Google Scholar
32	Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ and Belldegrun AS: Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int. 102:692–696. 2008.PubMed/NCBI View Article : Google Scholar
33	Hakenberg OW: Comment on Di Silverio et al: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008. 80:451–453, Urol Int 80: 454;. 2008.PubMed/NCBI View Article : Google Scholar
34	Roberts E, Cossigny DA and Quan GM: The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer. 2013(418340)2013.PubMed/NCBI View Article : Google Scholar
35	Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y, Li PY, Wang M, Lin JS and He XX: MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. Oncotarget. 6:29527–29542. 2015.PubMed/NCBI View Article : Google Scholar
36	Zhao X, Mohan R, Özcan S and Tang X: MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 (MAP4K4) in pancreatic beta-cells. J Biol Chem. 287:31155–31164. 2012.PubMed/NCBI View Article : Google Scholar
37	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005.PubMed/NCBI View Article : Google Scholar
38	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007.PubMed/NCBI View Article : Google Scholar
39	Zhang ZL, Bai ZH, Wang XB, Bai L, Miao F and Pei HH: miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. PLoS One. 10(e0118814)2015.PubMed/NCBI View Article : Google Scholar
40	Lee YH, Kim SY and Bae YS: Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells. Mol Cells. 37:620–627. 2014.PubMed/NCBI View Article : Google Scholar
41	Sun P, Hu JW, Xiong WJ and Mi J: miR-186 regulates glycolysis through Glut1 during the formation of cancer-associated fibroblasts. Asian Pac J Cancer Prev. 15:4245–4250. 2014.PubMed/NCBI View Article : Google Scholar
42	Cui G, Cui M, Li Y, Liang Y, Li W, Guo H and Zhao S: MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells. Tumour Biol. 35:8933–8937. 2014.PubMed/NCBI View Article : Google Scholar